Form 8-K - Current report:
SEC Accession No. 0001493152-25-007880
Filing Date
2025-02-21
Accepted
2025-02-21 16:30:26
Documents
18
Period of Report
2025-02-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51802
2 ex10-1.htm EX-10.1 23443
3 ex10-2.htm EX-10.2 61118
4 ex99-1.htm EX-99.1 24462
5 ex10-1_001.jpg GRAPHIC 8802
6 ex99-1_001.jpg GRAPHIC 2292
  Complete submission text file 0001493152-25-007880.txt   381121

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE prph-20250217.xsd EX-101.SCH 3027
8 XBRL LABEL FILE prph-20250217_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE prph-20250217_pre.xml EX-101.PRE 24173
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3727
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 25652441
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)